1 / 24

2008 Family & Professionals Conference

2008 Family & Professionals Conference. BEANTOWN: The SMA Revolution. Master Plan. Everything builds from the base:. Conference reflects these stages. COMMUNITY. Master Plan. Everything builds from the base:. Conference reflects these stages. CARE/MANAGEMENT. COMMUNITY. Master Plan.

milek
Download Presentation

2008 Family & Professionals Conference

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. 2008 Family & Professionals Conference BEANTOWN: The SMA Revolution

  2. Master Plan Everything builds from the base: Conference reflects these stages. COMMUNITY

  3. Master Plan Everything builds from the base: Conference reflects these stages. CARE/MANAGEMENT COMMUNITY

  4. Master Plan Everything builds from the base: Conference reflects these stages. EXISTING DRUGS CARE/MANAGEMENT COMMUNITY

  5. Master Plan Everything builds from the base: Conference reflects these stages. TREATMENT EXISTING DRUGS CARE/MANAGEMENT COMMUNITY

  6. Master Plan Everything builds from the base: Conference reflects these stages. CURE TREATMENT EXISTING DRUGS 2008 CARE/MANAGEMENT COMMUNITY

  7. Stages To a Treatment and Cure: 1st – Manage – with Care. 2nd – Slow – with Existing Drugs. 3rd – Stop – with New Drugs. 4th – Reverse – with a Cure.

  8. 1) SMA Community Orphan Disease: • Everything starts with the community. • Small market – too risky for companies (and government) to get involved at start. • Fundraising – over $40 Million to date. • Over time, if successful, will see transition from Community: • plus Government, • plus Companies.

  9. 2008 Conference – SMA Community • Invested over $2 Million since 1990 to bring community together every year. • Networking – Families and Researchers: • Opening, Lunches, Banquet, Carnival, Wonderful Life…… • Informal Opportunities. • Key Aspect - Attractive to the outside. • Legislative update – advocate.

  10. 2) Care/Management • Sharing and implementing best practices. • Families and physicians working together. • No effect on underlying cause. • Everyday items – special for SMA.

  11. 2) 2008 Conference - Care/Management • Informal sharing is just as important: • Workshops: • Share Your Experiences. • “Talk it Outs” with Al. • Standard of Care – Breathing, Feeding, Movement, Illness: • Workshops: • Respiratory Care I & II, Care for III, Ortho Management.

  12. 3) Existing Drugs - Slow • PBA, VPA, HU. • Designed for other diseases: • Urea Cycle, Epilepsy, Sickle Cell. • Cheap and quick to test (relatively): • Generally shown to be safe already. • Long shots – not likely to be very effective . • Builds SMA clinical trials infrastructure.

  13. 1. CARNI-VAL Type I 2. Stop SMA 3. Nptune 01 4. Nptune 02 5. Trophos 19622 6. VALIANT 7. Stanford HU Type I 8. HU Taiwan 3) 2008 Conference – Existing Drugs • New General Session: • Saturday – Therapeutic Approaches. • Sunday Q&A: Two Trials Recently Completed: Stanford HU in Type II/III AND Project Cure SMA CARNI-VAL Phase II

  14. 4) AND 5) Treatment AND Cure • Failure is the rule: • 9 out of 10 entering clinical trials fail. • Plan and prepare for this: • SMA needs 10 programs into clinic. • Cell replacement: • Even more risky, • But high potential. New Drugs/Treatment Stop Cure Reverse

  15. Clinical Development Preclinical: Discovery 4 AND 5) 2008 Conference – Treatment/Cure • Sunday Q&A: • Drug Development Panel • Clinical/Medical Panel FDA Approval Assay Dev. Screening Hit to Lead Lead Optimization Pre-Clinical Safety Clinical Trials Phase I, II, III Target ID Clinical Candidate IND FIH NDA Paratek Tetracyclines Quinazolines

  16. Conference reflects these stages Everything builds from the base: CURE TREATMENT EXISTING DRUGS 2008 CARE/MANAGEMENT COMMUNITY

  17. Progress 20002008 • Conference Attendees:275

  18. Progress 20002008 • Conference Attendees:275 750

  19. Progress 20002008 • Conference Attendees:275 750 • Companies in SMA:1

  20. Progress 20002008 • Conference Attendees:275 750 • Companies in SMA:1 23

  21. Progress 20002008 • Conference Attendees:275 750 • Companies in SMA:1 23 • Drug Discovery Programs:1

  22. Progress 20002008 • Conference Attendees:275 750 • Companies in SMA:1 23 • Drug Discovery Programs:1 15

  23. Progress 20002008 • Conference Attendees:275 750 • Companies in SMA:1 23 • Drug Discovery Programs:1 15 • Active Clinical Trials: 4

  24. Progress 20002008 • Conference Attendees:275 750 • Companies in SMA:1 23 • Drug Discovery Programs:1 15 • Active Clinical Trials: 4 12

More Related